
Efecte - Solid Growth Streak Continues

Redeye retains its positive view of Efecte following the Q1 report. Strong New Sales and Uplift compensated for the previously announced uptick in churn, although from a very low level. While getting mixed signals from customers and potential customers, Efecte sticks to its 2023 guidance. We leave our forecast and Base Case unchanged.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Efecte - Solid Growth Streak Continues